

# BIOINFORMANT

## Mesenchymal Stem Cells, Advances & Applications



1ST AND ONLY MARKET RESEARCH FIRM TO  
SPECIALIZE IN THE STEM CELL INDUSTRY

# **TABLE OF CONTENTS**

## **1. REPORT OVERVIEW**

- 1.1 Statement of the Report
- 1.2 Target Demographic
- 1.3 Report Sources
- 1.4 Purpose of the Report
  - 1.4.1 To Survey Recent MSC Advancements
  - 1.4.2 To Provide a “Snapshot” of Global MSC Market
  - 1.4.3 To Assess Opportunities for Commercialization
  - 1.4.4 To Identify Major Market Players and Assess the Competitive Environment
  - 1.4.5 To Identify Existing and Emerging Trends
  - 1.4.6 To Identify Critical Opportunities and Threats within the MSC Market
- 1.5 Executive Summary
- 1.6 Introduction

## **2. MESECHYMAL STEM CELLS (MSCS): AN OVERVIEW**

- 2.1 The Impact of MSCs on Regenerative Medicine
- 2.2 Timeline of MSC Nomenclature
- 2.3 Sources of MSCs
  - 2.3.1 Bone Marrow-Derived MSCs (BM-MSCs)
  - 2.3.2 Adipose-Derived MSCs (AD-MSCs)
  - 2.3.3 Umbilical Cord-Derived MSCs (UC-MSCs)
- 2.4 Cell Surface Markers in MSCs
- 2.5 In Vitro Differentiation Potentials of MSCs
- 2.6 Soluble Factors Secreted by MSCs

## **3. MANUFACTURE OF MESENCHYMAL STEM CELLS**

- 3.1 Methods of Isolation of MSCs
- 3.2 From Conventional Cultures to Bioreactors
  - 3.2.1 Monolayer Culture Systems
  - 3.2.2 Bioreactor-Based Cell Expansion
  - 3.2.3 Stirred Tank Bioreactor
  - 3.2.4 Rocking Bioreactor
  - 3.2.5 Hollow Fiber Bioreactors
  - 3.2.6 Fixed-Bed Bioreactors
- 3.3 Main Features of Commercial Bioreactors
- 3.4 Microcarriers used for the Expansion of MSCs
- 3.5 Downstream Processing of MSCs
  - 3.5.1 Cell Detachment and Separation
  - 3.5.2 Cell Washing and Concentration
  - 3.5.3 Safety and Potency Assays
  - 3.5.4 Surface Markers for Identification during MSC Manufacture

## **4. COMPARISON OF AUTOLOGOUS AND ALLOGENEIC MSC MANUFACTURE**

- 4.1 Manufacturing Cost Comparison
  - 4.1.1 Cost Differential
  - 4.1.2 Cost of Donor Screening and Testing
  - 4.1.3 Cost for Release Testing
- 4.2 Comparison of the Two Business Models
  - 4.2.1 Risk of Immune Reaction
  - 4.2.2 Risk of Cross Contamination
  - 4.2.3 Commercially Attractive Option
- 4.3 Cost Breakdown in MSC Manufacturing
- 4.4 Opportunities for Cost Reduction
- 4.5 Partial Automation vs. Full Automation
  - 4.5.1 Partial Automation: The Most Attractive Option

## **5. SMALL SCALE PROCESSING OF MSCS**

- 5.1 Model Design
- 5.2 Culture Media

## **6. LARGE-SCALE EXPANSION OF MSCS**

- 6.1 The Four Common Bioprocessing Strategies for Large-Scale Expansion
- 6.2 Commonly Used Sources of MSCs for Large-Scale Expansion
- 6.3 The Commonly Used Culture Medium for the Large-Scale Expansion of MSCs
  - 6.3.1 Expansion Ratio Achieved with Different Culture Media
- 6.4 Comparison between Large-Scale Bioprocessing Strategies
- 6.5 Contract Manufacturing for Cell Therapies
  - 6.5.1 Contract Manufacturing Organizations (CMOs)
  - 6.5.2 Contract Development and Manufacturing Organizations (CDMOs)
    - 6.5.2.1 Major Services Offered by CMOs
    - 6.5.2.2 Regional Distribution of CMOs
- 6.6 Global Cell Therapy Manufacturing Capacity
  - 6.6.1 Major Cell Therapy CMOs/CDMOs in the U.S
  - 6.6.2 Major CMOs/CDMOs for Cell Therapy Manufacturing in Europe

## **7. ESTIMATED CONSUMPTION OF MSCS IN THE INDUSTRY**

- 7.1 Consumption of MSCs in Academic and Preclinical Settings
- 7.2 MSC Consumption in Clinical Settings
- 7.3 Consumption of MSCs by Target Indications in Clinical Trials
- 7.4 Future Consumption through 2030
  - 7.4.1 Consumption for MSC Therapeutics
  - 7.4.2 Consumption for Engineered Tissues and Organs
  - 7.4.3 MSC Consumption by MSC-Derived Products
  - 7.4.4 MSC Consumption in Emerging Industries
- 7.5 Cost of MSCs per Patient used in Clinical Trials by Indication

## **8. PUBLISHED SCIENTIFIC PAPERS ON MSCS**

- 8.1 Number of Papers on MSCs & iPSCs Compared
- 8.2 Number of Papers on MSCs by Source
- 8.3 Number of Papers Published on Clinical Trials Involving MSCs
  - 8.3.1 Number of Papers on Clinical Trials using MSCs for Specific Diseases

## **9. CLINICAL TRIALS OF MSCS, MSC-BASED COVID-19, MSC-EXOSOMES**

- 9.1 Analysis of Data from ClinicalTrials.gov
- 9.2 Sources of MSCs for Clinical Trials
- 9.3 Autologous vs. Allogeneic MSCs
- 9.4 Regional Distribution of MSC-Based Clinical Trials
  - 9.4.1 Major Countries Involved in MSC-Based Clinical Trials
- 9.5 Types of Funding for MSC-Based Clinical Trials
- 9.6 Types of MSC-Based Clinical Trials
- 9.7 MSC-Based Clinical Trials by Phase of Development
- 9.8 Clinical Trials Involving MSCs for the Treatment of COVID-19
  - 9.8.1 MSC-Based COVID-19 Clinical Trials by Geography
- 9.9 Clinical Trials Involving MSC-Derived Exosomes
- 9.10 NIH Funding for MSC Research
- 9.11 CIRM's Funding for MSC Projects
  - 9.11.1 CIRM Funding for MSC-Based Clinical Trials

## **10. CURRENT SUB-OPTIMAL CLINICAL OUTCOMES & SOLUTIONS**

- 10.1 To Overcome Challenges Arising from MSC Manufacture
  - 10.1.1 Heterogeneity in the MSC Product
- 10.2 Cryopreservation and Culture Rescue
  - 10.2.1 Bioengineering Solutions to Boost MSC Function
  - 10.2.2 Engineering MSCs to Carry Anti-Cancer “Trojan Horses”
- 10.3 Overcoming Clinical Challenges Related to Infusion
  - 10.3.1 Local Administration
  - 10.3.2 Insufficient Retention and Survival
  - 10.3.3 Strategies to Improve Local Administration
- 10.4 To Overcome Clinical Challenges from the Host

## **11. MODIFICATION OF MSCS**

- 11.1 Genetic Modification
  - 11.1.1 Gene Modification to Improve Migration
  - 11.1.2 Gene Modification to Improve Adhesion
  - 11.1.3 Genetic Modification to Improve Survival
  - 11.1.4 Genetic Modification to Reduce Premature Senescence
- 11.2 Preconditioning Modifications
  - 11.2.1 Preconditioning to Improve Migration
  - 11.2.2 Preconditioning to Improve Adhesion
  - 11.2.3 Preconditioning to Improve Survival
  - 11.2.4 Preconditioning to Reduce Senescence
- 11.3 Therapeutic Application of Modified MSCs
  - 11.3.1 Modified MSCs for Neurological Conditions

- 11.3.2 Modified MSCs for Cardiovascular Diseases
- 11.3.3 Modified MSCs for Lung Injury
- 11.3.4 Modified MSCs for Diabetes

## **12. MAJOR DISEASES ADDRESSED BY MSCS IN CLINICAL TRIALS**

- 12.1 Clinical Trials using MSCs for Autoimmune Diseases
- 12.2 Clinical Trials using MSCs for Cardiovascular Diseases
- 12.3 Clinical Trials using MSCs for Neurodegenerative Diseases
- 12.4 Clinical Trials using MSCs for Bone and Cartilage Diseases

## **13. PRESENT STATUS OF MESENCHYMAL STEM CELL INDUSTRY**

- 13.1 Sources of MSCs for Research and Clinical Applications
- 13.2 Allogeneic Products Gaining Traction
- 13.3 MSC-Based Products with Marketing Approval
  - 13.3.1 Alofisel
  - 13.3.2 Stemirac
  - 13.3.3 Stempeucel
  - 13.3.4 Temcell HS
  - 13.3.5 Neuronata-R
  - 13.3.6 Prochymal (Remestemcel-L)
  - 13.3.7 Cupistem
  - 13.3.8 Cartistem
  - 13.3.9 Cellgram-AMI
  - 13.3.10 Queencell
- 13.4 Currently Marketed MSC-Based Bone Matrices
  - 13.4.1 Osteocel
  - 13.4.2 AlloStem
  - 13.4.3 Cellentra VCBM
  - 13.4.4 HiQCell
  - 13.4.5 Trinity ELITE
  - 13.4.6 Map3
  - 13.4.7 Trinity Evolution
  - 13.4.8 Carticel
  - 13.4.9 Chondron
  - 13.4.10 DeNovo NT
  - 13.4.11 Chondroselect
  - 13.4.12 Ossron
  - 13.4.13 JACC
  - 13.4.14 MACI
  - 13.4.15 Ortho-ACI
  - 13.4.16 Spherox
  - 13.4.17 Ossgrow
  - 13.4.18 Cartigrow
  - 13.4.19 ViviGen
  - 13.4.20 Bio4
  - 13.4.21 Cartiform
- 13.5 From Whole Cell MSC Therapy to MSC-Derived Exosome Therapy
  - 13.5.1 Advantages of MSC-Derived Exosomes
  - 13.5.2 Contents of MSC-Derived Exosomes

- 13.5.3 Exosomes as Diagnostics
- 13.5.4 Exosomes as Drug Delivery Vectors
- 13.6 MSC-Based Therapy for COVID-19
- 13.7 MSC-Based Clean Meat Production
- 13.8 Stem Cell-Based Cosmetics
- 13.8.1 Marketed Stem Cell-Based Cosmetic Products

## 14. MARKET ANALYSIS

- 14.1 Price Tags for MSC-Based Cell Therapy (CT) Treatment
- 14.2 Price Tags for MSC-Based Matrices
- 14.3 Market Size of MSC-Based Therapies
- 14.4 Global Market for MSC-based Therapeutics
- 14.5 Global Demand for Mesenchymal Stem Cells (MSCs)
  - 14.5.1 MSCs Required for Academic and Preclinical Research
  - 14.5.2 Required MSCs for Clinical Trials
  - 14.5.3 MSCs Required for Developing MSC-Based Therapeutics
  - 14.5.4 MSCs Required for Developing MSC-Derived Products
  - 14.5.5 MSCs Required for Emerging Industries
  - 14.5.6 Global Market Size for Mesenchymal Stem Cells
- 14.6 Market Share of MSC-Based Business Segments

## 15. COMPANY PROFILES

- 15.1 101 Bio
  - 15.1.1 Exosome Services
- 15.2 Adipomics, Inc.
- 15.3 Aegle Therapeutics
  - 15.3.1 Aegle's Platform Technology
    - 15.3.1.1 Epidermolysis Bullosa
- 15.4 Aethlon Medical, Inc.
  - 15.4.1 Hemopurifier in Cancer
- 15.5 AgeX Therapeutics, Inc.
  - 15.5.1 PureStem Technology
  - 15.5.2 Induced Tissue Regeneration (iTR)
  - 15.5.3 UniverCyte
- 15.6 Alexerion Biotech Corp.
  - 15.6.1 Drug Development
- 15.7 AlloSource, Inc.
  - 15.7.1 Products
    - 15.7.1.1 AlloStem
- 15.8 American CryoStem Corporation
  - 15.8.1 Services
    - 15.8.1.1 ATGRAFT Fat Storage
    - 15.8.1.2 Adult Stem Cell Program
  - 15.8.2 Products
    - 15.8.2.1 CELECT Tissue Harvesting System
    - 15.8.2.2 ATCELL-AD-MSCs
    - 15.8.2.3 ACSelerateMAX Growth Medium
- 15.9 American Type Culture Collection (ATCC)
  - 15.9.1 Stem Cell Products

- 15.10 AMS Biotechnology, Ltd. (AMSBIO)
  - 15.10.1 Products
- 15.11 Anemocyte S.r.l.
  - 15.11.1 Total GMP Capacity
  - 15.11.2 Product Types
  - 15.11.3 Manufacturing Services
- 15.12 Anjarium Biosciences
  - 15.12.1 Anjarium's Hybridosome Platform
- 15.13 Anterogen, Co., Ltd.
  - 15.13.1 Products
    - 15.13.1.1 Cupistem Injection
    - 15.13.1.2 Queencell Injection
- 15.14 Apceth Biopharma GmbH
  - 15.14.1 Global Services
  - 15.14.2 Assay Development Services
- 15.15 Aruna Bio
  - 15.15.1 AB126
- 15.16 Athersys, Inc.
  - 15.16.1 MultiStem
- 15.17 Avalon GloboCare Corp.
  - 15.17.1 Avalon's Core Platforms
- 15.18 Axol Bioscience, Ltd.
  - 15.18.1 Products
- 15.19 Azymus Therapeutics
  - 15.19.1 AZ Platform
- 15.20 BioCat GmbH
  - 15.20.1 Exosome Purification Kits
- 15.21 BioFluidica
  - 15.21.1 Technology Platform
- 15.22 Bio-Techne
  - 15.22.1 Total GMP Capacity
  - 15.22.2 Product Types
- 15.23 BioVision, Inc.
- 15.24 Baylx, Inc.
  - 15.24.1 Product Candidates
- 15.25 BrainStorm Cell Therapeutics
  - 15.25.1 MSC-NTF Cells
- 15.26 Capricor Therapeutics
  - 15.26.1 Exosome Program
- 15.27 Catalent Pharma Solutions
  - 15.27.1 Cell Therapy Expertise
- 15.28 CCRM
  - 15.28.1 Total GMP Capacity
  - 15.28.2 Product Types
  - 15.28.3 Manufacturing Services
- 15.29 CellResearch Corporation, Pte Ltd.
  - 15.29.1 Umbilical Cord Lining Stem Cells
- 15.30 Celltex Therapeutics Corporation
  - 15.30.1 Therapy Services
- 15.31 Ciloa
  - 15.31.1 Exosome Customization Technology

- 15.32 Codiak Biosciences
  - 15.32.1 engEx Platform
  - 15.32.2 exoASO-STAT6
  - 15.32.3 exoIL-12
- 15.33 Corestem, Inc.
  - 15.33.1 Neuronata-R
- 15.34 CO-DON AG
  - 15.34.1 M-ACT
- 15.35 Cognate BioServices, Inc.
  - 15.35.1 Total GMP Capacity
  - 15.35.2 Product Types
- 15.36 Creative Bioarray
- 15.37 Creative Biolabs
  - 15.37.1 Products
  - 15.37.2 Services
- 15.38 Cynata Therapeutics, Ltd.
  - 15.38.1 Cymerus Platform
  - 15.38.2 GvHD
  - 15.38.3 Critical Limb Ischemia
  - 15.38.4 Asthma
  - 15.38.5 Heart Attack
  - 15.38.6 Diabetic Wounds
  - 15.38.7 Coronary Artery Disease (CAD)
  - 15.38.8 Acute Respiratory Distress Syndrome (ARDS)
  - 15.38.9 Sepsis
  - 15.38.10 Osteoarthritis
- 15.39 DePuy Synthes
  - 15.39.1 ViviGen
- 15.40 Direct Biologics
  - 15.40.1 ExoFlo
- 15.41 EVerZom
  - 15.41.1 Services
- 15.42 Evox Therapeutics, Ltd.
  - 15.42.1 Protein Therapeutics – REPLACE
  - 15.42.2 RNA Therapeutics – CORRECT
- 15.43 Exerkine Corp.
  - 15.43.1 Clinical Development
    - 15.43.1.1 Genetic Diseases
    - 15.43.1.2 Aging-Associated Diseases
- 15.44 ExoCan Healthcare Technologies, Pvt. Ltd.
  - 15.44.1 Technology
    - 15.44.1.1 ExoEnrich Exosome Isolation Kit
    - 15.44.1.2 ExoEngineering
- 15.45 ExoCoBio, Co., Ltd.
  - 15.45.1 Products
- 15.46 Exogenus Therapeutics
- 15.47 EXoPERT
  - 15.47.1 EXo-i
- 15.48 Exopharm
  - 15.48.1 LEAP Technology
  - 15.48.2 Cevaris & Plexaris



- 15.49 Exosome Diagnostics, Inc.
  - 15.49.1 ExoDx Prostate Test
- 15.50 ExosomePlus
- 15.51 Exosome Sciences
  - 15.51.1 TauSome Biomarker
- 15.52 Exosomics S.p.A.
  - 15.52.1 ExoRef
  - 15.52.2 SeleCTEV Enrichment Kits
  - 15.52.3 SoRTEV Enrichment Kit
- 15.53 Fraunhofer Institute for Cell Therapy and Immunology
  - 15.53.1 Total GMP Capacity
  - 15.53.2 Product Types
  - 15.53.3 Manufacturing Services
- 15.54 HansaBioMed Life Sciences, Ltd.
  - 15.54.1 Products
- 15.55 Hope Biosciences, LLC
  - 15.55.1 Hope's Cell Culture Process
- 15.56 Japan Tissue Engineering, Co., Ltd.
  - 15.56.1 JACC
- 15.57 JCR Pharmaceuticals, Co., Ltd.
  - 15.57.1 TEMCELL HS Inj.
- 15.58 Kimera Labs, Inc.
- 15.59 Lonza Group Ltd.
  - 15.59.1 Total GMP Capacity
  - 15.59.2 Product Types
  - 15.59.3 Manufacturing Services
- 15.60 Mantra Bio
  - 15.60.1 Partnering
- 15.61 Medipost, Co., Ltd.
  - 15.61.1 Cartistem
- 15.62 MDimune
  - 15.62.1 BioDrone Technology
- 15.63 NanoSomix, Inc.
  - 15.63.1 Technology
- 15.64 NanoView Biosciences
  - 15.64.1 Products
    - 15.64.1.1 ExoView R 100
    - 15.64.1.2 ExoView Tetraspanin Kits
- 15.65 NeurExo Sciences
- 15.66 Nipro Corporation
  - 15.66.1 Stemirac
- 15.67 Novus Biologicals, LLC
  - 15.67.1 Exosomes Research Tools
- 15.68 NuVasive, Inc.
  - 15.68.1 Osteocel Family
- 15.69 OmniSpirant Limited
  - 15.69.1 Technology
- 15.70 Orthocell, Ltd.
  - 15.70.1 Ortho-ATI
  - 15.70.2 CelGro
- 15.71 Orthofix Medical, Inc.

- 15.71.1 Trinity ELITE
- 15.71.2 Trinity EVOLUTION
- 15.72 Osiris Therapeutics, Inc.
  - 15.72.1 Cartiform
  - 15.72.2 Bio4
- 15.73 Pharmicell, Co., Ltd.
  - 15.73.1 Cellgram-AMI
  - 15.73.2 Stem Cell Culture Media Cosmetics
- 15.74 Pluristem Therapeutics, Inc.
  - 15.74.1 Products
  - 15.74.2 PLX-PAD
  - 15.74.3 PLX-R18
  - 15.74.4 PLX-Immune
  - 15.74.5 Partnerships and Collaborations
    - 15.74.5.1 Collaboration with NASA
    - 15.74.5.2 Collaboration with NIAID
    - 15.74.5.3 Collaboration with U.S. Department of Defence (DOD)
    - 15.74.5.4 License Agreement with Chart Industries, Inc.
    - 15.74.5.5 Collaboration with Thermo Fisher Scientific
    - 15.74.5.6 Partnership with Cha Biotech
- 15.75 Regeneus, Ltd.
  - 15.75.1 HiQCell
- 15.76 Regrow Biosciences, Pvt., Ltd.
  - 15.76.1 Ossgrow
  - 15.76.2 Cartigrow
- 15.77 ReNeuron
  - 15.77.1 Exosome Platform
- 15.78 RoosterBio
  - 15.78.1 Products
  - 15.78.2 Services
- 15.79 RoslinCT
  - 15.79.1 Total GMP Capacity
  - 15.79.2 Product Types
  - 15.79.3 Manufacturing Services
- 15.80 RTI Surgical, Inc.
  - 15.80.1 Map3 Allograft Chips
- 15.81 Sentien Biotechnologies, Inc.
  - 15.81.1 SBI-101
  - 15.81.2 Pipeline
- 15.82 STEMCELL Technologies, Inc.
  - 15.82.1 Products
- 15.83 Stemedica Cell Technologies, Inc.
  - 15.83.1 BioSmart Technology
  - 15.83.2 Pipeline
- 15.84 Stematters Biotechnologia e Medicina Regenerativa SA
- 15.85 Stempeutics Research, Pvt., Ltd.
  - 15.85.1 Stempeucel
  - 15.85.2 Stempeutron
  - 15.85.3 Stempeucare (Cutisera)
- 15.86 System Biosciences, LLC
  - 15.86.1 Products

- 15.86.2 Services
- 15.87 Takeda Pharmaceuticals U.S.A., Inc.
  - 15.87.1 Alofisel
- 15.88 Tempo Bioscience
  - 15.88.1 Products
    - 15.88.1.1 Human Cell Models
    - 15.88.1.2 Services & Alliances
- 15.89 Tavec Pharma
  - 15.89.1 Technology
- 15.90 United Therapeutics Corp.
  - 15.90.1 Unexisome
- 15.91 Vericel Corporation
  - 15.91.1 MACI
  - 15.91.2 Carticel
- 15.92 Versatope Therapeutics
  - 15.92.1 VT-105
- 15.93 Vesigen Therapeutics, Inc.
  - 15.93.1 Technology
- 15.94 Waisman Biomanufacturing
  - 15.94.1 Total GMP Capacity
  - 15.94.2 Product Types
  - 15.94.3 Manufacturing Services
- 15.95 WuXi Advanced Therapies
  - 15.95.1 Total GMP Capacity
  - 15.95.2 Product Types
- 15.96 XOSTem, Inc.
- 15.97 Zen-Bio, Inc.
  - 15.97.1 Products
    - 15.97.1.1 Human Exosomes
  - 15.97.2 Contract Services
- 15.98 Zimmer Biomet
  - 15.98.1 Cellentra

## **INDEX OF FIGURES**

- FIGURE 3.1: Monolayer Culture Systems
- FIGURE 3.2: Stirred Tank Bioreactor
- FIGURE 3.3: Rocking Bioreactor
- FIGURE 3.4: Hollow Fiber Bioreactors
- FIGURE 3.5: Fixed-Bed Bioreactors
- FIGURE 3.6: Single-Use Harvestainer for Small Scale Application
- FIGURE 3.7: Single-Use Harvestainer for Large Scale Application
- FIGURE 4.1: CoG in MSC Manufacturing
- FIGURE 4.2: Impact of Head Count on Overall CoG per Batch
- FIGURE 4.3: CoG Breakdown in Partially-Automated MSC Manufacturing
- FIGURE 4.4: Cost Breakdown in Fully Automated MSC Manufacturing
- FIGURE 4.5: Higher Throughput in Partially Automated Facilities
- FIGURE 5.1: Diagrammatic Representation of SelecT Automated Platform by Sartorius
- FIGURE 5.2: Model of a Clean Room in a Small-Scale Manufacturing Facility

FIGURE 6.1: The Four Common Bioprocessing Strategies  
FIGURE 6.2: Large-Scale Expansion of MSCs by Source  
FIGURE 6.3: Commonly used Culture Media in the Large-Scale Expansion of MSCs  
FIGURE 6.4: Major Services Offered by CMOs  
FIGURE 6.5: Regional Distribution of CMOs  
FIGURE 7.1: Share of Published Papers by Type  
FIGURE 7.2: Consumption of MSCs in Academic and Preclinical Settings  
FIGURE 7.3: MSC Consumption in Clinical Settings  
FIGURE 7.4: Consumption of MSCs by Target Indications in Clinical Trials  
FIGURE 8.1: Number of Published Papers on MSCs between 2010 and 2020  
FIGURE 8.2: Number of Published Papers for MSCs and iPSCs Compared, 2010-2020  
FIGURE 8.3: Number of Papers on MSCs by Source  
FIGURE 8.4: Number of Papers on Clinical Trials Involving MSCs  
FIGURE 8.5: Percent Share of Specific Diseases in Clinical Trials  
FIGURE 9.1: Distribution of Clinical Trials involving MSCs across the World, 2020  
FIGURE 9.2: Clinical Trials Involving MSCs by Source  
FIGURE 9.3: Clinical Trials Involving Autologous and Allogeneic MSCs  
FIGURE 9.4: Distribution of MSC-Based Clinical Trials by Geography, 2020  
FIGURE 9.5: Type of Funding for MSC-Based Clinical Trials  
FIGURE 9.6: The Three Types of Ongoing MSC-Based Clinical Trials, 2020  
FIGURE 9.7: MSC-Based Clinical Trials by Phase of Development, 2020  
FIGURE 9.8: MSC-Based COVID-19 Clinical Trials by Geography  
FIGURE 10.1: Bioengineering Solutions to Boost the Function of MSC  
FIGURE 10.2: Bioengineering Solutions for Improving Administration of MSCs  
FIGURE 10.3: Solutions to Overcome Host Factors  
FIGURE 11.1: Four Focal Points of Enhancement of MSC's Properties during Modification  
FIGURE 11.2: The Cycle of Naïve MSCs to Modified MSCs for Clinical Application  
FIGURE 12.1: Major Diseases Addressed by MSCs in Clinical Trials  
FIGURE 12.2: Percent Share of Autoimmune Diseases in Clinical Trials using MSCs  
FIGURE 12.3: Percent Share of MSC by Source in Trials for Cardiovascular Diseases  
FIGURE 12.4: Percent Shares of Neurodegenerative Diseases in Clinical Trials using MSCs  
FIGURE 12.5: Percent Share of MSC by Source in Trials for Bone & Cartilage Diseases  
FIGURE 14.1: Percent Share of Marketed CT, GT and TE Products  
FIGURE 14.2: Percent Share of CT Products by Indication  
FIGURE 14.3: Market for MSC-Based Cell Therapy Products by Geography, 2020-2027  
FIGURE 14.4: Global Market for Mesenchymal Stem Cells by Geography, 2020-2027  
FIGURE 14.5: Market Share of MSCs by Business Segment

## **INDEX OF TABLES**

TABLE 2.1: Timeline of MSC Nomenclature  
TABLE 2.2: Sources of MSCs  
TABLE 2.3: Advantages and Disadvantages of BM-MSCs  
TABLE 2.4: Advantages and Disadvantages of AD-MSCs  
TABLE 2.5: Advantages and Disadvantages of UC-MSCs  
TABLE 2.6: Positive and Negative Markers for MSCs Derived from Different Sources  
TABLE 2.7: In Vitro Differentiation Potentials of MSCs  
TABLE 2.8: Soluble Factors Secreted by MSCs  
TABLE 3.1: Initial Story of MSCs: A Snapshot

TABLE 3.2: Methods of Isolation of MSCs and Corresponding Culture Media

TABLE 3.3: A Snapshot of Commercially Available Culture Systems

TABLE 3.4: Main Features of Commercially Available Bioreactors

TABLE 3.5: Microcarriers used for the Expansion of MSCs

TABLE 3.6: Basic Assays for MSCs

TABLE 3.7: Cell Surface Markers on MSCs and Fibroblasts

TABLE 4.1: Cost of Manufacturing Allogeneic MSCs

TABLE 4.2: Cost of Manufacturing Autologous MSCs

TABLE 4.3: Comparison of Allogeneic and Autologous Therapies

TABLE 4.4: Cost of Goods (CoG) in MSC Manufacturing

TABLE 4.5: CoG Breakdown in Partially Automated MSC Manufacturing

TABLE 4.6: Cost Breakdown in Fully Automated MSC Manufacturing

TABLE 4.7: Higher Throughput in Partially Automated Facilities

TABLE 5.1: Key Process and Cost Assumptions

TABLE 5.2: Quality Control Panel with Cost Assessments

TABLE 5.3: Additional Supporting Labor Cost Assumptions

TABLE 5.4: Additional Supporting Facility and Process Assumptions

TABLE 6.1: Large-Scale Expansion of MSCs by Method, Cell Source and Media

TABLE 6.2: Expansion Ratio Achieved with Different Culture Media

TABLE 6.3: Comparison between Large-Scale Bioprocessing Strategies

TABLE 6.4: Regional Distribution of CMOs

TABLE 6.5: Global Cell Therapy Manufacturing Capacity

TABLE 6.6: Major CDMOs and CMOs in North America

TABLE 6.7: Major CDMOs and CMOs in Europe

TABLE 7.1: Cost of MSCs per Patient in Clinical Trials by Indication

TABLE 8.1: Number of Published Papers on MSCs between 2010 and 2020

TABLE 8.2: Number of Papers on MSCs & iPSCs Compared between 2010 and 2020

TABLE 8.3: Number of Papers on MSCs by Source

TABLE 8.4: Number of Papers on Clinical Trials Involving MSCs, 2010-2020

TABLE 8.5: Number of Papers on Trials using MSCs for Specific Diseases, 2010-2020

TABLE 9.1: Number of Clinical Trials Involving MSCs by Region as of Apr. 2020

TABLE 9.2: Clinical Trials Involving MSCs by Source

TABLE 9.3: Clinical Trials Involving Autologous vs. Allogeneic MSCs

TABLE 9.4: Distribution of MSC-Based Clinical Trials by Geography, 2020

TABLE 9.5: Number of MSC-Based Clinical Trials by Country as of 2020

TABLE 9.6: Type of Funding for MSC-Based Clinical Trials, 2020

TABLE 9.7: The Three Types of Ongoing MSC-Based Clinical Trials, 2020

TABLE 9.8: MSC-Based Clinical Trials by Phase of Development, 2020

TABLE 9.9: Number of COVID-19 Clinical Trials by Country

TABLE 9.10: Examples of Clinical Trials involving MSC-Derived Exosomes

TABLE 9.11: NIH Funding for Research on MSCs, 2020

TABLE 9.12: CIRM-Funded MSC Projects

TABLE 9.13: MSC-Based Clinical Trials Funded by CIRM

TABLE 10.1: Examples of Bioengineered MSCs Loaded with Therapeutics

TABLE 10.2: Examples of Bioengineered MSCs used as Anti-Cancer Trojan Horses

TABLE 11.1: Select Cases of Modified MSC Applications and Therapeutic Outcome

TABLE 12.1: Select MSC-Based Clinical Trials for Autoimmune Diseases

TABLE 12.2: Select MSC-Based Clinical Trials for Cardiovascular Diseases

TABLE 12.3: Select MSC-Based Clinical Trials for Neurodegenerative Diseases

TABLE 12.4: Select MSC-Based Clinical Trials for Bone and Cartilage Diseases

TABLE 13.1: Examples of Completed Clinical Trials involving MSCs

TABLE 13.2: MSC Products with Marketing Approval

TABLE 13.3: Marketed Products Containing MSCs in Matrices

TABLE 13.4: Disease Conditions Studied using Stem Cell Conditioned Medium

TABLE 13.5: List of Stem Cell-Based Cosmetics

TABLE 14.1: Price Tags of MSC-Based Approved CT Products

TABLE 14.2: Price Tags for Select MSC Progenitor-Based Products

TABLE 14.3: Global Market for MSC-Based Cell Therapy by Geography, 2020-2027

TABLE 14.4: Global Market for Mesenchymal Stem Cells by Geography, 2020-2027

TABLE 15.1: Alexerion's Exosome-Based Pipeline

TABLE 15.2: BrainStorm's Product Pipeline

TABLE 15.3: Celltex Therapeutics' Clinical Trials

TABLE 15.4: The Cellgram Pipeline from Pharmicell

TABLE 15.5: Pluristem's Clinical Pipeline

TABLE 15.6: Sentien's Pipeline

TABLE 15.7: Stemedica's Clinical Pipeline

## About BioInformant:

As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving Fortune 500 companies that include Pfizer, GE Healthcare, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

To learn more, visit [BioInformant.com](http://BioInformant.com).

